Ferring International Center SA - Company Profile
Powered by
All the data and insights you need on Ferring International Center SA in one report.
- Save hours of research time and resources with
our up-to-date Ferring International Center SA Strategy Report
- Understand Ferring International Center SA position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Ferring International Center SA (Ferring), a subsidiary of Ferring Holding SA, is a research-driven, specialty biopharmaceutical company. Its primary activities include research and development in reproductive medicine, women's health, gastroenterology, and urology. Ferring's product portfolio includes treatments for reproductive medicine and maternal health, gastroenterology and microbiome, urology and uro-oncology, endocrinology, and orthopedics. Ferring's products are used by patients seeking treatments in the areas of reproductive health, gastroenterology, and urology, among others. The company has a global presence with manufacturing sites and R&D centers in countries such as China, Denmark, Brazil, Israel, Japan, India, the UK, and the US. Ferring Pharmaceuticals is headquartered in Saint-Prex, Switzerland.
Ferring International Center SA premium industry data and analytics
Products and Services
Products | Services | Brands |
---|---|---|
Reproductive Medicine & Maternal Health | Late Stage Collaborations | Menopur |
Gastroenterology & Microbiome | Drug Discovery Partnering | Endometrin/ Lutinus |
Urology & Uro-Oncology | Carbetocin Ferring | |
XYZ | XYZ | |
XYZ | XYZ | |
XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2023 | Contracts/Agreements | In December, the company entered into an agreement with PharmaBiome to advance innovative microbiome-based biological therapies in gastrointestinal. |
2023 | Contracts/Agreements | In August, the company entered into an agreement with Royalty Pharma for new intravesical gene therapy Adstiladrin (nadofaragene firadenovec-vncg). |
2023 | Contracts/Agreements | In April, the company and BioInnovation entered into a collaboration to accelerate progress in the field of women's health. |
Competitor Comparison
Key Parameters | Ferring International Center SA | Max Zeller Soehne AG | Med Discovery SA | Mepha Pharma AG | Release Therapeutics |
---|---|---|---|---|---|
Headquarters | Switzerland | Switzerland | Switzerland | Switzerland | Switzerland |
City | Saint-Prex | Romanshorn | Epalinges | Basel | Genève |
State/Province | Waadt | Thurgau | - | Basel-Stadt | - |
No. of Employees | 7,000 | 142 | - | 190 | - |
Entity Type | Private | Private | Private | Private | Private |
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Jean-Frederic Paulsen | Chairman | Executive Board | 2023 | - |
Lars Rebien Sorensen | Vice Chairman | Executive Board | 2023 | - |
Dominic Moorhead | Chief Financial Officer; Executive Vice President | Senior Management | 2017 | - |
Curt McDaniel | Chief Legal Officer; Secretary - Board | Senior Management | 2020 | - |
Pierre-Yves Berclaz | Chief Medical Officer; Executive Vice President | Senior Management | 2023 | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward